Gane E J, Portmann B C, Naoumov N V, Smith H M, Underhill J A, Donaldson P T, Maertens G, Williams R
Institute of Liver Studies, Kings's College School of Medicine and Dentistry, London, United Kingdom.
N Engl J Med. 1996 Mar 28;334(13):815-20. doi: 10.1056/NEJM199603283341302.
End-stage cirrhosis related to hepatitic C virus (HCV) is a common reason for liver transplantation, although viremia ia known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis.
A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group. A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation.
Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P=0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype 1b was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable.
After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection.
丙型肝炎病毒(HCV)相关的终末期肝硬化是肝移植的常见原因,尽管在大多数情况下病毒血症会持续存在。我们研究了肝移植后持续性HCV感染对患者和移植物存活的影响,以及HCV基因型和供体与受体之间HLA匹配程度对复发性肝炎严重程度的影响。
对1982年1月至1994年4月间接受肝移植的149例HCV感染患者进行了中位时间为36个月的随访;将623例因终末期慢性肝病接受肝移植的无HCV感染患者作为对照组。对来自HCV感染受者的总共528份肝活检标本进行了复查,包括按计划在移植后1年获取的82份和按计划在5年获取的39份。此外,对91例HCV阴性患者在移植后5年获取了活检标本。
149例HCV感染患者1年后的累积生存率为79%,3年后为74%,5年后为70%,而HCV阴性移植受者的相应生存率分别为75%、71%和69%(P = 0.12)。在移植后存活超过6个月的130例丙型肝炎感染患者中,15例(12%)在其最近一次肝活检时无慢性肝炎证据(中位随访时间,20个月),70例(54%)有轻度慢性肝炎(中位时间,35个月),35例(27%)有中度慢性肝炎(中位时间,35个月),10例(8%)有肝硬化(中位时间,51个月)。149例患者中有27例在中位时间303天后出现移植物丢失,其中5例为HCV相关肝硬化,3例为HCV相关胆汁淤积性肝炎。HCV 1b基因型感染与更严重的移植物损伤相关,而所用的主要免疫抑制方案以及供体与受体之间HLA不匹配程度对该变量无显著影响。
对于HCV相关肝硬化患者进行肝移植后,持续性HCV感染可导致严重的移植物损害,且这种损害在感染HCV 1b基因型的患者中比其他基因型患者更常见。5年后,有HCV感染和无HCV感染患者的移植物和总体生存率相似。